Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Thousands of melanoma patients in Europe have no access to new drugs

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1061

Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia

Prof Sekulovic meets with ecancertv at ESMO 2016 to discuss the regulatory and funding issues that block drug access for thousands of cancer patients, especially in Southern and Eastern Europe.

She describes the reimbursement models of some healthcare funders, and how delays or complications these models limits the suitability of therapies available to many patients.

Prof Sekulovic sets out steps that are being taken to streamline drug access by regulatory bodies and pharmaceutical suppliers, including reforms and stratification of therapies.

For more details, you can read the news story here.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation